Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 1—January 2022
Research Letter

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Nicolas LambertComments to Author , Solène Dauby, Dominique Dive, Bernard Sadzot, and Pierre Maquet
Author affiliation: University Hospital of Liège, Liège, Belgium

Main Article

Figure

Clinical course and evolution of JC virus load in CSF of 77-year-old patient undergoing atezolizumab therapy for progressive multifocal leukoencephalopathy. CSF, cerebrospinal fluid; IRAEs, immune-related adverse events; JCV, JC virus.

Figure. Clinical course and evolution of JC virus load in CSF of 77-year-old patient undergoing atezolizumab therapy for progressive multifocal leukoencephalopathy. CSF, cerebrospinal fluid; IRAEs, immune-related adverse events; JCV, JC virus.

Main Article

Page created: October 22, 2021
Page updated: December 02, 2021
Page reviewed: December 02, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external